Optional product analytics
With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
The biggest opportunity lies in the announced strategic separation of the Health Information Systems business segment.
Expiration of non-repeating $0.48/share H1 IEEPA tariff refunds coinciding with operational friction during the North American ERP cutover inventory reversal in Q3 2026.
Solventum Corporation (NYSE: SOLV) is rated Buy with a house fair value of $103.66 per share, offering an implied upside of 19.75% from its October 14, 2026 price of $86.57. While near-term reported revenues absorb ERP cutover order shifts and SKU rationalization, core surgical consumable volumes and strategic portfolio separation provide robust compounding potential.2
Solventum presents an attractive risk-adjusted total return profile, trading at a 16.5% discount to its synthesized fair value of $103.66. The market price of $86.57 values the equity at 13.09x forward earnings,, a noticeable discount compared to medical technology peers such as West Pharmaceutical (37.81x) and ResMed (17.65x). This multiple compression reflects near-term operational noise surrounding the post-spin separation from 3M and North American ERP system migration.2
Operational execution in Q2 2026 demonstrated underlying resilience. Solventum delivered 9.5% organic sales growth and adjusted diluted EPS of $2.55 (up 50.9% year-over-year). Consequently, management raised full-year 2026 guidance across organic revenue growth (2.5% to 3.0%), adjusted EPS ($7.10 to $7.20), and free cash flow ($200M to $300M),,. Organic procedure trends remain durable, with hospital demand displaying steady volume gains.3
The announced plan to separate the Health Information Systems business segment within 12 to 18 months represents a significant value catalyst. Generating $1.4B in annual revenue with an operating margin of 39.6% in H1 2026,, HIS separation will transform Solventum into a dedicated MedTech pure-play while generating proceeds to de-lever debt and fund share repurchases.3
Trading at 13.09x forward earnings, Solventum offers a 16.5% discount to house fair value of $103.66, providing a wide margin of safety against broader peer multiples.2
The planned separation of the Health Information Systems unit (generating $1.4B revenue and 39.6% H1 operating margin) allows direct monetization to accelerate balance sheet deleveraging and share repurchases,.3
Solventum Corporation is a Buy, supported by a 19.75% upside to house fair value of $103.66,. The market's focus on temporary ERP cutover timing masks durable procedural demand, structural margin expansion toward 23.8%, and catalytic portfolio unlocking through the HIS separation,.
Solventum Corporation is an established global healthcare technology company, originally formed via the corporate spin-off of 3M Company's health care business in 2024. The company develops, manufactures, and markets clinical solutions across four primary segments: MedSurg, Dental Solutions, Health Information Systems, and retained filtration operations within All Other. Solventum serves hospitals, surgical centers, health systems, dental clinics, and clinician offices worldwide, generating $8,325M in total revenue in FY2025.
The MedSurg franchise ($4,817M FY2025 revenue) supplies advanced wound care therapies, negative pressure wound dressings, infection prevention supplies, IV site dressings, and surgical supplies,. Dental Solutions ($1,349M FY2025 revenue) offers restorative materials, bonding agents, and orthodontic products spanning the clinical lifecycle of the tooth,. Health Information Systems ($1,360M FY2025 revenue) delivers clinical documentation, speech recognition, and automated coding software deployed in more than 75% of U.S. hospitals,.
The stress test synthesizes four compounding operational risks: the expiration of non-repeating IEEPA tariff refunds ($0.48 EPS in H1 2026), operational friction in restocking inventory post-ERP cutover, structural volume drag from active SKU pruning (~100 bps), and balance sheet leverage from $5,079M in debt. Under this compounded scenario, operating margins contract to 19.5% and revenue growth decelerates by 500 bps, leading to an enterprise valuation contraction of over 30%. However, Solventum's strong market positions across essential consumables and announced strategic portfolio options provide downside resilience.
Solventum Corporation possesses a Narrow economic moat grounded in sticky clinical relationships, high procedural switching costs in MedSurg consumables, and mission-critical hospital software integration,. Its core franchise centers on MedSurg ($4,817M FY2025 revenue) and Dental Solutions ($1,349M FY2025 revenue),, which benefit from high recurring procedural consumption across hospitals, clinics, and dental practices globally.
The Health Information Systems segment, which management announced its intent to separate, serves over 75% of U.S. hospitals and processes 660 million clinical documents monthly. This high-margin software business (39.6% segment operating margin in H1 2026) exemplifies exceptional customer captivity. However, in core consumables, commoditization pressures and active SKU rationalization (~100 bps revenue drag) restrict the overall franchise moat rating to Narrow rather than Wide.
Moat durability is assessed as Stable. Procedure volumes across acute hospital admissions remain steady, with management confirming absence of demand softening across MedSurg, Dental, and HIS in Q2 2026. Solventum's disciplined R&D investments and tuck-in acquisitions, such as the Acera Surgical acquisition in advanced wound matrices,, reinforce intellectual property protections and ensure steady product replenishment across clinical settings.
None of the valuation methods used to calculate Fair value relies on a separate assumption about how long the competitive advantage lasts.
The highlighted cell is Fair value when every assumption sits at its base level ($103.66). Each row and column shows what Fair value becomes when one assumption moves.
A free-cash-flow drop test is not available in this run; use the discount-rate and terminal-growth grid as the primary valuation pressure test.
An earnings beat driven by organic consumable growth and sustained operating margin expansion confirms thesis execution, while house rating policy maintains the active constructive recommendation.
Medical equipment and supplies industry benchmarks show an average capex-to-revenue ratio of 4.5% and a capex-to-depreciation ratio of 0.8x. Solventum's FY2025 capex was $379M on $8,325M revenue (4.55% capex/revenue),, and H1 2026 capital expenditures stood at $167M. Because comprehensive industry capacity utilization and supply lead-time metrics are unavailable, the capital cycle view is demand-led and evidence-limited.4
In an industry expansion, rising elective surgical procedure volumes, global population aging, and acute care automation drive mid-single-digit volume compounding and pricing realization across medical consumable and health IT platforms.
In a healthcare industry downturn, hospital freezes and supply chain insourcing constrain medical technology adoption, though recurring consumable procedure volumes remain comparatively insulated relative to capital equipment.
Solventum warrants a moderate conviction sizing of 3% to 5% of total portfolio equity. High recurring consumable demand, strong software integration, and substantial discount to fair value support the allocation, while outstanding post-spin debt obligations ($5,079M) and ERP operational cutover risks justify prudent risk-budget exposure.
Risk is actively managed by tracking quarterly free cash flow progression against guided levels, verifying inventory normalization post-ERP cutover, and monitoring debt leverage metrics. Position exposure remains capped at 5% to account for balance sheet indebtedness ($5,079M total debt).
Solventum possesses sticky clinical positions across acute care hospitals, recurring consumable revenue, and durable margin expansion potential toward 23.8%, offering an attractive entry multiple of 13.09x forward P/E.2
The stock trades at a 16.5% discount to fair value. Transitory operational noise around the ERP cutover and the upcoming separation of the high-margin HIS software business create an attractive catalyst-driven opportunity.
Solventum does not currently pay a regular dividend and carries $5,079M in total debt, making it less appropriate for income-seeking investors until balance sheet de-leveraging is further advanced.
Solventum Corporation is rated Buy with a synthesized house fair value of $103.66 per share, offering 19.75% upside from the October 14, 2026 price of $86.57. The investment thesis centers on the resilience of Solventum's core clinical consumable franchises, steady operating margin expansion toward 23.8%, and substantial value unlock from the planned HIS portfolio separation.23
Market concerns regarding reported revenue contraction in H2 2026 mistake temporary ERP inventory timing shifts and proactive SKU pruning for structural deterioration,. Solventum's strong competitive positioning, disciplined tuck-in M&A strategy, and free cash flow recovery support multi-year compound growth.
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
The records this analysis drew on, as they stood when it was run.
Over 80% of sales derive from high-margin procedural consumables embedded in hospital clinical protocols, enabling operating margin expansion toward 23.8% by FY2030.
Geographically, Solventum operates an extensive global footprint, generating $4,668M of FY2025 revenue in the United States and $3,657M across international markets,. On August 5, 2026, the company announced its intent to separate its Health Information Systems segment to emerge as a pure-play medical technology company.
In the Bear case (25% probability), expiration of the $0.48 H1 tariff benefit coincides with persistent supply chain disruption following the North American ERP migration,. Adjusted operating margins compress below 19.5%, hospital demand softens, and credit spreads on $5,079M of debt widen, lifting WACC to 8.67%. Intrinsic valuation contracts toward $72.63.
FY2026 operating margin guidance of 22.2%-22.7% relies on ~120 bps of temporary IEEPA tariff refunds ($0.48 EPS in H1),. Expiration of tariff benefits combined with ERP replenishment friction and standalone corporate dis-synergies would compress adjusted operating margins below 19.5%, inflicting an estimated 24.5% fair value impairment.3
Solventum trades at 13.09x forward P/E, while peers ALGN trades at 11.46x and COO at 11.55x. With FY2026 reported revenue declining -1.15% and post-event EPS growth stalling at 1.45% in FY2027, valuation derating toward a 20% haircut (10.8x P/E) aligns SOLV with lower-growth medical consumable peers, generating a 20% fair value impact.2
Solventum carries $5,079M of debt ($4,573M long-term + $506M current) against just $403M of cash as of June 30, 2026, producing elevated credit vulnerability. Slower cash conversion (H1 FCF -$129M) threatens credit metrics, expanding debt spreads and driving WACC up by +100 bps from 7.67% to 8.67%, leading to an 18.2% fair value impact.1
Management guided Q3 revenue growth to -3% to -4% as advance orders reverse and is pruning lower-margin SKUs (~100 bps drag). Continued hospital budget pressures, supply disruptions post-ERP, and dental volume stagnation could suppress 5-year revenue trajectory by 500 bps below consensus expectations, driving a 31% fair value impairment.3
The five developments that would weaken our investment case.
Operating margins falling below 19.5% would indicate that expiration of temporary IEEPA tariff refunds ($0.48 EPS in H1) unmasked severe corporate dis-synergies and ERP replenishment cost inflation, breaking the multi-year path toward 23.8% operating margins.
Current:24.2% H1 2026 adjusted operating margin / 22.2%-22.7% FY2026 guidance
Alert if< 19.5% adjusted operating margin
A revenue contraction sharper than the guided -3% to -4% Q3 advance order reversal would signal permanent customer attrition or distribution bottlenecking post-ERP cutover rather than planned timing shifts,.
Current:Guidance of -3% to -4% reported revenue contraction in Q3 2026
Alert ifQ3 reported revenue contraction exceeding -4.0%
Failure of H2 2026 free cash flow to turn strongly positive to reach the guided $200M-$300M range indicates unmodeled spin separation leakage, preventing debt paydown against $5,079M in total obligations.
Current:$200M to $300M FY2026 guidance / H1 2026 free cash flow of -$129M,
Alert ifFull-year FY2026 free cash flow < $200M or H2 cash flow conversion < 50%
Cost of capital expanding by 100 bps above 8.67% due to credit spread widening on debt burdens would directly impair intrinsic enterprise valuation by approximately 18%.
Current:7.67% computed WACC / 6.06% pre-tax cost of debt
Alert if> 8.67% computed WACC (+100 bps expansion)
Organic consumable volume growth decelerating below -1.5% would indicate that hospital procurement freezes and competitor share losses in Dental or MedSurg are eroding core franchise volume, impairing long-term compounding.
Current:+2.5% to +3.0% FY2026 guidance (+3.5% to +4.0% ex-SKUs),
Alert if5-year revenue CAGR falling below -1.5%
Solventum generates underlying economic profit well above its cost of capital. Solventum's H1 2026 adjusted operating margin stood at 24.2%, significantly outperforming the broader industry median operating margin of 15.5%. Across the house forecast schedule, operating margins normalize to 22.5% in FY2026 and expand to 23.8% by FY2030, easily clearing the computed WACC of 7.67% and moderate cost of equity of 8.66%.1
Each lens answers a different valuation question. Only included lenses set Fair value; floors and diagnostics provide context.
Project SBC-adjusted EPS, discount each year's earnings at cost of equity, then add a Gordon-growth terminal value.
Under the moderate discount rate, $24.65 comes from forecast-period earnings and $96.17 from the long-term value, totaling $121.
Apply a terminal P/E to the dated forward EPS path, then discount that future share value back to the analysis date.
Add depreciation to net income, subtract maintenance capex, divide by diluted shares, and apply a normalized valuation multiple.
Solve for the growth rate that makes the model value equal the report-date share price.
In the Base case (55% probability), Solventum executes against its post-spin operating schedule. Transitory Q3 2026 order reversals normalize into positive organic growth in Q4 (3% to 4%), yielding full-year FY2026 organic growth of 2.5% to 3.0%. Operating margins expand from 22.5% to 23.8% over five years, driving EPS to $8.21 by FY2030. Intrinsic fair value settles at $103.66.3
In the Bull case (20% probability), successful North American ERP replenishment and rapid execution of the Health Information Systems separation unlock significant shareholder value,. Core MedSurg procedure growth accelerates above 4.0% as SKU rationalization concludes, and operating margins expand toward 24.5%. Cash proceeds from HIS de-lever the balance sheet and accelerate share repurchases, lifting fair value to $129.62.3
Results meeting management's FY2026 adjusted EPS guidance of $7.10-$7.20 and organic growth of 2.5%-3.0% validate the base case valuation thesis.
A material earnings miss driven by persistent ERP execution failures or sharply contracting adjusted operating margins would impair intrinsic value, warranting a rating downgrade.
Solventum's earnings quality reflects substantial variance between GAAP and non-GAAP metrics due to spin-off transition accounting. Key adjustments stem from separation-related costs, intangible asset amortization, litigation expenses, and restructuring charges. In addition, first-half operating results included non-recurring benefits from tariff refunds booked in the second quarter. Normalizing for separation friction and non-repeating tariff benefits demonstrates underlying operating cash durability, though transition costs will persist through the second half.3
Consensus estimate momentum post-Q2 2026 earnings is flat. Following the August 5, 2026 release, consensus adjusted EPS for FY2026 remained unchanged at $6.55 before rising to $7.14 on October 14, 2026 to match raised guidance,. Similarly, FY2027 consensus EPS was unchanged at $7.09 post-event and settled at $7.25 by mid-October. Revenue revision cohorts likewise tracked flat immediately post-event, reflecting market caution regarding second-half ERP inventory adjustments.3
Verifying that the Q3 sales contraction remains confined to the guided -3% to -4% range confirms that customer demand is intact and restocking is progressing smoothly.3
Assessing whether operating margins sustain above 22.2% in H2 2026 without the $0.48 H1 tariff benefit validates standalone cost structures.3
De-leveraging is essential to reduce pre-tax interest costs ($125M in H1 2026) and maintain credit stability.
| $8.17B |
| $8.13B |
| $8.20B |
| $8.25B |
| $8.33B |
| +0.5% |
| Gross profit | $4.92B | $4.70B | $4.69B | $4.59B | $4.45B | -2.5% |
| Operating income | $1.88B | $1.69B | $1.69B | $1.04B | $2.18B | +3.8% |
| Net income | $1.46B | $1.34B | $1.35B | $479.0M | $1.56B | +1.6% |
| EPS (diluted) | — | $7.78 | $7.79 | $2.76 | $8.88 | +4.5% |
| EBITDA | $2.48B | $2.27B | $2.23B | $1.53B | $2.55B | +0.7% |
| R&D | $766.0M | $767.0M | $758.0M | $775.0M | $739.0M | -0.9% |
| SG&A | $2.28B | $2.24B | $2.30B | $2.78B | $3.08B | +7.8% |
Cash generation is undergoing a sharp post-spin inflection. In H1 2026, GAAP operating cash flow was $38M and free cash flow was -$129M (after $167M capex), weighed down by $308M of 3M separation costs and working capital builds. However, Q2 2026 demonstrated significant positive momentum, generating $227M in operating cash flow and $144M in free cash flow ($83M capex). Consequently, management raised full-year 2026 free cash flow guidance to $200M-$300M. As non-operating separation expenses diminish beginning in Q4 2026, free cash conversion is modeled to normalize toward 70%-80% of net income.3
Solventum's post-spin capital allocation framework prioritizes balance sheet deleveraging, disciplined tuck-in M&A, and direct shareholder returns. Solventum closed H1 2026 with $4,573M in long-term debt and $506M in short-term debt ($5,079M total debt) against $403M in cash. Pre-tax cost of debt is 6.06%. The company completed the tuck-in acquisition of Acera Surgical in December 2025 to bolster advanced wound care and accelerated its $1.0B share repurchase program, repurchasing $355M of common stock in H1 2026 (including nearly 4.0M shares for $288M in Q2),. Proceeds from the planned HIS separation are expected to be deployed toward debt reduction and direct shareholder returns.
Solventum's return on capital is positioned for sustained improvement as post-spin transition investments abate. In FY2025, Solventum generated $2,181M in EBIT on $8,325M in revenue,. Operating margins are projected to expand from 22.5% in FY2026 to 23.8% in FY2030, which will steadily elevate return on invested capital as invested capital scales modestly.
With an effective tax rate of 19.26% and steady operating profitability, Solventum's post-tax return on capital comfortably exceeds its computed WACC of 7.67% and its moderate cost of equity of 8.66%, generating durable economic profit.
In H1 2026, adjusted operating margins expanded 340 bps year-over-year to 24.2%. Management's FY2026 guidance calls for 22.2% to 22.7%, and the house forecast path projects steady expansion to 23.8% by FY2030.
Operational restructuring and standalone footprint optimization provide a durable margin compounding driver that offsets transitory separation friction.
Reported FY2026 revenue is modeled to decline -1.15%, but full-year organic growth is guided at +2.5% to +3.0% (+3.5% to +4.0% excluding ~100 bps SKU rationalization),.
The apparent top-line deceleration reflects portfolio cleanup and timing shifts rather than organic share loss, setting up an acceleration to 3.56% revenue growth in FY2027.
Solventum carries $5,079M of total debt ($4,573M long-term + $506M current) with $403M cash, generating $125M in H1 net interest expense.
Deleveraging remains paramount to narrow credit spreads, lower WACC (7.67%), and unlock equity value.
| Revenue | $8,325,000,000 |
|---|---|
| Cost of revenue | $3,874,000,000 |
| Gross profit | $4,451,000,000 |
| Operating expenses | $2,270,000,000 |
| Operating income | $2,181,000,000 |
| Non-operating items and tax | -$625,000,000 |
| Net income | $1,556,000,000 |
| Total assets | $14,294,000,000 |
|---|---|
| Cash | $878,000,000 |
| Current assets | $3,859,000,000 |
| Total liabilities | $9,245,000,000 |
| Current liabilities | $3,136,000,000 |
| Shareholders’ equity | $5,050,000,000 |
| Net income | $1,556,000,000 |
|---|---|
| Operating inflow | $2,206,000,000 |
| Depreciation and amortization | $489,000,000 |
| Stock-based compensation | $161,000,000 |
| Operating cash flow | $369,000,000 |
| Operating outflow | $1,837,000,000 |
| Cash available | $3,935,000,000 |
| Beginning cash | $762,000,000 |
| Investing inflow | $2,797,000,000 |
| Exchange-rate effect | $7,000,000 |
| Financing outflow | $3,057,000,000 |
| Net debt repayment | $3,070,000,000 |
| Ending cash | $878,000,000 |
| Investing cash flow | $2,797,000,000 |
| Financing cash flow | -$3,057,000,000 |
Point-in-time financial data used in the 2026-10-14 analysis.
| Period | Revenue | EBITDA | Net income | Operating cash flow | Free cash flow | Capex | Depreciation and amortization | Stock-based compensation | Share repurchases | Dividends paid | Net debt issuance | Investing cash flow | Financing cash flow | Beginning cash | Ending cash | Cash and investments | Total debt | Operating margin | ROIC | WACC | ROIC − WACC spread |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2020-12-31 | $7.3B | $2B | $1.1B | $2B | $1.8B | $271M | $599M | $35M | — | — | — | $228M | -$2.2B | — | — | — | — | 19.6% | — | — | — |
| 2021-12-31 | $8.2B | $2.5B | $1.5B | $2.2B | $1.9B | $277M | $597M | $38M | — | — | — | -$278M | -$2B | — | $91M | $91M | $112M | 23.0% | — | — | — |
| 2022-12-31 | $8.1B | $2.3B | $1.3B | $1.7B | $1.4B | $251M | $578M | $37M | — | — | $0 | -$253M | -$1.5B | $91M | $61M | $61M | $95M | 20.8% | — | — | — |
| 2023-12-31 | $8.2B | $2.2B | $1.3B | $1.9B | $1.6B | $290M | $561M | $39M | — | — | $0 | -$230M | -$1.6B | $61M | $194M | $600M | $0 | 20.6% | — | — | — |
| 2024-12-31 | $8.3B | $1.5B | $479M | $1.2B | $805M | $380M | $555M | $112M | — | — | $8B | -$380M | -$240M | $194M | $762M | $762M | $8B | 12.6% | — | 6.7% | — |
| 2025-12-31 | $8.3B | $2.5B | $1.6B | $369M | -$10M | $379M | $489M | $161M | — | — | -$3.1B | $2.8B | -$3.1B | $762M | $878M | $878M | $5B | 26.2% | — | 6.8% | — |
Solventum Corporation (SOLV) trades at 13.1x forward earnings against a peer median of 14.6x. Its EV/EBITDA of 17.2x compares with a peer median of 14.9x. The comparison uses 4 peers: The Cooper Companies Inc., Align Technology Inc., ResMed Inc. and West Pharmaceutical Services Inc., as of 2026-10-14.
Solventum occupies a defensive, cash-generative niche within the healthcare sector, insulated from capital budget cyclicality because its portfolio emphasizes essential procedural consumables and administrative coding software rather than big-ticket hospital capital equipment. High recurring consumable utilization protects unit volumes across macroeconomic cycles.
| October 14, 2026 price level ($86.00 - $87.00)2 | Initiate primary position tranche (50% of targeted allocation). | Captures an immediate 16.5% discount to house fair value ($103.66) and a depressed 13.09x forward P/E multiple. |
| Pullback below $82.00 | Deploy secondary tranche (remaining 50% allocation). | Capitalizes on headline weakness during the Q3 reported revenue contraction (-3% to -4%), capturing an even wider margin of safety. |
Expiration of non-repeating $0.48/share H1 IEEPA tariff refunds coinciding with operational friction during the North American ERP cutover inventory reversal in Q3 2026. The planned reversal of $125M in advance customer orders shifts Q3 reported revenue into contraction (-3% to -4%), while post-spin standalone overhead and supply chain replenishment challenges prevent operating expense absorption once non-repeating tariff benefits cease. Operating margins compress below 19.5%, leading to an estimated 24.5% fair value impairment and restricting free cash flow required to service $5,079M in debt. H2 2026 adjusted operating margin holding above the 22.2% guidance lower bound and full-year free cash flow reaching the $200M-$300M range.3
Not every cited input appears here: internal calculations and intermediate model outputs have no external record, and some citations could not be matched to one.
| ALGN |
| Align Technology Inc. |
| $10.1B |
| 11.5x |
| 2.4x |
| 10.0x |
| 10.2% |
| 18.2% |
| RMD | ResMed Inc. | $32.9B | 17.6x | 5.8x | 15.9x | 24.3% | 30.9% |
| WST | West Pharmaceutical Services Inc. | $26.6B | 37.8x | 8.0x | 28.6x | 19.1% | 22.5% |
